Warren Buffett Comments on Valeant Pharma (VRX)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/21/2026
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
- Abbott plans to spin off its nutrition unit as a standalone public company
- Alphabet shares drop ahead of earnings next week
- Supermicro raises Q1 FY2027 revenue outlook on AI demand
- Dow outperforms as Wall Street rises, healthcare stocks lead gains
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
Valeant (VRX) 10-K Not Enough to Bring Back the Bulls or Scare The Bears - BMO Capital
May 2, 2016 9:56 AM EDTBMO Capital analyst Alex Arfaei reiterated a Market Perform rating and lowered his price target on Valeant Pharmaceuticals (NYSE: VRX) to $44.00 (from $66.00), saying the 10K is not enough to bring back the bulls or scare the bears.
Arfaei commented, "The good news was that we didnt find any new smoking guns in the 10-K. Valeant has averted technical default on its debt, and based on our... More
Valeant's (VRX) Debt Covenants Remain a Concern After 10K Filing - Piper Jaffray
May 2, 2016 7:43 AM EDTPiper Jaffray analyst, David Amsellem, noted that Valeant's (NYSE: VRX) 10K for 2015 contained one kernel of good news: it cured the default on its senior notes related to the late filing. Unfortunately that was "the only piece of good news". Here are the problems:
Wholesaler inventory... More



